<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03082560</url>
  </required_header>
  <id_info>
    <org_study_id>2016P002620</org_study_id>
    <nct_id>NCT03082560</nct_id>
  </id_info>
  <brief_title>Design and Validation of a New Assessment Tool for Lichen Planopilaris</brief_title>
  <official_title>Design and Validation of a New Assessment Tool for Lichen Planopilaris, the Boston Grade of Activity in Lichen Planopilaris (Boston GOAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study's Primary Objective is to design and validate a grading system for objective and
      accurate assessment of lichen planopilaris.

      Secondary Objectives:

        -  To assess change in symptoms such as pain and itch using a Numeric Rating Scale(NRS)
           scores and quality of life using the Dermatology Life Quality Index (DLQI) scores

        -  To correlate this grading system with patient skin biopsies evaluating disease activity
           on a microscopic level

        -  To correlate this grading system with digital global photography and trichoscopy
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2017</start_date>
  <completion_date type="Anticipated">January 10, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 10, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Boston Grade of Activity in Lichen Planopilaris (Boston GOAL)</measure>
    <time_frame>6 months</time_frame>
    <description>Design and validate a grading system for objective and accurate assessment of lichen planopilaris.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lichen Planopilaris of Scalp</condition>
  <condition>Lichen Plano-Pilaris</condition>
  <condition>Lichen Planopilaris</condition>
  <condition>Frontal Fibrosing Alopecia</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Healthy adult patients with lichen planopilaris</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Boston Grade of Activity in Lichen Planopilaris</intervention_name>
    <description>A clinical assessment tool to objectively and accurately measure activity and severity in lichen planopilaris over time.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy adult subjects with lichen planopilaris
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects in general good health between the ages of 18 and 80 years old

          2. Clinical and histologic diagnosis of lichen planopilaris

          3. Subject is able to understand and sign informed consent

          4. Subject is able to complete the study and comply with study procedures

          5. Subject has no known allergy to non-toxic ink

          6. Subjects should be managed by an Massachusetts General Hospital dermatologist for
             their lichen planopilaris for the duration of the study

        Exclusion Criteria:

        Eligible subjects will be excluded from participation if they meet any of the following
        criteria:

          1. Presence of dermatoses that might interfere with LPP diagnosis and/or evaluation such
             as seborrheic dermatitis or psoriasis

          2. Other selected concomitant causes of hair loss, including discoid lupus erythematosus,
             central centrifugal cicatricial alopecia (CCCA), telogen effluvium

          3. Abnormal TSH laboratory value &gt;1 standard deviation above normal within last year

          4. Any significant medical condition that may prevent the patient from participating in
             the study according to the investigator's assessment

          5. Any known allergy to non-toxic ink Related to Biopsy

          6. History of poor wound healing or blood-clotting abnormality

          7. History of keloid formation or hypertrophic scarring

          8. Regular intake of high doses of aspirin or anti-coagulant medications

          9. Hypersensitivity to local anesthetics

         10. History of poorly controlled diabetes mellitus

         11. Pregnant, nursing or planning a pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maryanne Senna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maryanne Senna, MD</last_name>
    <phone>617-643-6699</phone>
    <email>msenna@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Athena Jane Manatis-Lornell, BA</last_name>
    <email>amanatislornell@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maryanne Senna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martina Porter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mariko Yasuda, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2017</study_first_submitted>
  <study_first_submitted_qc>March 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2017</study_first_posted>
  <last_update_submitted>March 30, 2018</last_update_submitted>
  <last_update_submitted_qc>March 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Maryanne Makredes Senna</investigator_full_name>
    <investigator_title>Dermatologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Lichen Planus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

